Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage | Zendy

Luãnna Liebscher Vidal | Zendy; André F. Santos | Zendy; Marcelo A. Soares | Zendy

Open Access

Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage

Author(s) -

Luãnna Liebscher Vidal,

André F. Santos,

Marcelo A. Soares

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv081

Subject(s) - simeprevir , genotype , virology , hepatitis c virus , ns5b , biology , sofosbuvir , viral load , hepatitis c , hepacivirus , medicine , virus , ribavirin , genetics , gene

Several direct-acting agents against the hepatitis C virus (HCV) NS3 protease and NS5b polymerase have been developed in recent years to improve treatment of this viral infection. Of these, simeprevir is currently recommended for HCV genotype 1 and 4 infections, but genotypic assessment for the presence of 80K is required prior to simeprevir administration due to the reduced susceptibility of genotype 1 viruses carrying that polymorphism. Because the prevalence of 80K at baseline in genotype 1 viruses varies between reports, we wanted to assess its worldwide prevalence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research